CTCX vs. LUCD, LNSR, CODX, MODD, DRIO, CTSO, RVP, XAIR, MDAI, and APYX
Should you be buying Carmell stock or one of its competitors? The main competitors of Carmell include Lucid Diagnostics (LUCD), LENSAR (LNSR), Co-Diagnostics (CODX), Modular Medical (MODD), DarioHealth (DRIO), Cytosorbents (CTSO), Retractable Technologies (RVP), Beyond Air (XAIR), Spectral AI (MDAI), and Apyx Medical (APYX). These companies are all part of the "surgical & medical instruments" industry.
Lucid Diagnostics (NASDAQ:LUCD) and Carmell (NASDAQ:CTCX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, community ranking, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.
In the previous week, Lucid Diagnostics had 1 more articles in the media than Carmell. MarketBeat recorded 4 mentions for Lucid Diagnostics and 3 mentions for Carmell. Carmell's average media sentiment score of 0.55 beat Lucid Diagnostics' score of 0.22 indicating that Lucid Diagnostics is being referred to more favorably in the media.
Carmell has a net margin of 0.00% compared to Carmell's net margin of -2,169.07%. Lucid Diagnostics' return on equity of -154.49% beat Carmell's return on equity.
Lucid Diagnostics has a beta of 1.63, indicating that its share price is 63% more volatile than the S&P 500. Comparatively, Carmell has a beta of 0.32, indicating that its share price is 68% less volatile than the S&P 500.
Lucid Diagnostics currently has a consensus price target of $2.75, suggesting a potential upside of 205.22%. Given Carmell's higher probable upside, analysts clearly believe Lucid Diagnostics is more favorable than Carmell.
Lucid Diagnostics received 25 more outperform votes than Carmell when rated by MarketBeat users.
74.0% of Lucid Diagnostics shares are owned by institutional investors. Comparatively, 24.2% of Carmell shares are owned by institutional investors. 4.8% of Lucid Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Carmell has lower revenue, but higher earnings than Lucid Diagnostics.
Summary
Lucid Diagnostics beats Carmell on 9 of the 13 factors compared between the two stocks.
Get Carmell News Delivered to You Automatically
Sign up to receive the latest news and ratings for CTCX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CTCX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
